Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL

NCT07058103 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Angioimmunoblastic T-Cell Lymphoma Recurrent
Angioimmunoblastic T-Cell Lymphoma Refractory

Interventions

DRUG: tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone

Sponsor

The Affiliated Hospital of Xuzhou Medical University